<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diagnosis and treatment of an acute reaction to a radiologic contrast agent
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diagnosis and treatment of an acute reaction to a radiologic contrast agent
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diagnosis and treatment of an acute reaction to a radiologic contrast agent
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stella K Kang, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            N Franklin Adkinson, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 02, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H272366529">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contrast administration for imaging is associated with a low rate of adverse reactions. Most are mild and self-limited. However, a small proportion of reactions do require treatment and, if left untreated, could prove life-threatening.
        </p>
        <p>
         The approach to the evaluation and management of a patient with an acute contrast reaction is described here and is based primarily on the evidence from iodinated contrast, used for computed tomography (CT) and angiography, and gadolinium-based contrast, used for magnetic resonance imaging (MRI). Management of an adverse reaction to gas-filled microbubble contrast agents used in ultrasound is similar, although these reactions are very uncommon and, as yet, not as well understood. (See
         <a class="medical medical_review" href="/z/d/html/5301.html" rel="external">
          "Contrast echocardiography: Contrast agents, safety, and imaging technique", section on 'Safety'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/96352.html" rel="external">
          "Contrast-enhanced ultrasound for the evaluation of liver lesions", section on 'Safety'
         </a>
         .)
        </p>
        <p>
         Appropriate measures to
         <strong>
          prevent
         </strong>
         recurrent contrast reaction to iodinated or gadolinium-based contrast, contrast-induced nephropathy, or nephrogenic systemic fibrosis as well as the evaluation of patients with a history of a contrast reaction in the nonurgent setting are discussed separately in:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113083.html" rel="external">
          "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">
          "Prevention of contrast-associated acute kidney injury related to angiography"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118730.html" rel="external">
          "Allergy evaluation of immediate hypersensitivity reactions to radiocontrast media"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3095881060">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravascular contrast agents used for computed tomography (CT) are iodinated and are distinct from those used in magnetic resonance imaging (MRI), which are gadolinium-based. Hence, they do not demonstrate crossreactivity and a past reaction to one type (ie, iodinated or gadolinium-based) does not preclude future use of the other [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The frequency of acute adverse reactions to contrast varies with the contrast type (ie, iodinated versus gadolinium-based) and its molecular properties (eg, ionicity, osmolality, ligand structure) [
         <a href="#rid1">
          1-7
         </a>
         ]. Contrast reactions have been observed with intra-arterial, intravenous (IV), enteral, and intraperitoneal administration. However, the vast majority of acute reactions are from intravascular administrations, which remain the basis for our understanding and approach to contrast reaction diagnosis and treatment. Cardiac adverse events are much more common during angiocardiography than intravenous contrast administration [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2894759070">
         <span class="h2">
          Incidence rates
         </span>
        </p>
        <p class="headingAnchor" id="H1869566434">
         <span class="h3">
          Iodinated contrast
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iodinated contrast is given for CT and in fluoroscopic interventions such as angiography. A list of iodinated contrast agents on the market and their molecular properties can be found in Appendix A of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acr.org%2F-%2Fmedia%2FACR%2FFiles%2FClinical-Resources%2FContrast_Media.pdf&amp;token=IQxLzDq4doJGUgaZgeIY01IKkxx3ydwNAD3trB6%2B2YV9VFCAnyLrNLHtmmp2EYMjzDheSEca6wwFKrqbXQpAQN3StB3oZduNC2r1%2B4NcHFs%3D&amp;TOPIC_ID=2075" target="_blank">
          American College of Radiology Manual on Contrast Media
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The rate of acute adverse reactions from nonionic low- or iso-osmolar iodinated contrast is approximately 0.15 to 0.7 percent with &gt;98 percent being mild and self-limited [
         <a href="#rid8">
          8-11
         </a>
         ]. Fatality from iodinated contrast has been estimated at 2 to 9 per one million administrations [
         <a href="#rid4">
          4,12
         </a>
         ]. The safety profile of the nonionic low- or iso-osmolar contrast currently in use is much better than the ionic high-osmolar agents of the past; consequently, the latter are no longer in use.
        </p>
        <p class="headingAnchor" id="H3012863426">
         <span class="h3">
          Gadolinium-based contrast
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gadolinium-based contrast agents (GBCAs) are classified according to ionicity (ionic or nonionic) and the chelating ligand (macrocyclic or linear). A list of GBCAs on the market and their molecular properties can be found in Appendix A of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acr.org%2F-%2Fmedia%2FACR%2FFiles%2FClinical-Resources%2FContrast_Media.pdf&amp;token=IQxLzDq4doJGUgaZgeIY01IKkxx3ydwNAD3trB6%2B2YV9VFCAnyLrNLHtmmp2EYMjzDheSEca6wwFKrqbXQpAQN3StB3oZduNC2r1%2B4NcHFs%3D&amp;TOPIC_ID=2075" target="_blank">
          American College of Radiology Manual on Contrast Media
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Rates of acute reactions to specific GBCAs range from 0.02 to 0.09 percent with &gt;96 percent being mild and self-limited [
         <a href="#rid13">
          13-17
         </a>
         ]. Severe, life-threatening reactions to GBCA, while extremely rare, have been reported [
         <a href="#rid18">
          18
         </a>
         ]. Nonionic agents with a linear chelate are associated with 5- to 10-fold lower acute reaction rates than those that are ionic or with a macrocyclic chelate [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3377024725">
         <span class="h1">
          SIGNS AND SYMPTOMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute reactions to contrast usually occur within 20 minutes of exposure but are generally defined as those occurring within an hour. They are classified as allergic-like or physiologic based upon the clinical presentation  (
         <a class="graphic graphic_table graphicRef121978" href="/z/d/graphic/121978.html" rel="external">
          table 1
         </a>
         ). Most life-threatening reactions occur within 20 minutes of contrast injection [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1019276151">
         <span class="h2">
          Allergic-like versus physiologic reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergic-like reactions are idiosyncratic, not related to dose, may occur in patients without prior exposure to the contrast agent, and do not predictably recur after each antigen exposure. The major risk factor is a history of a previous severe reaction to the same type of contrast agent [
         <a href="#rid10">
          10,17,19
         </a>
         ].
        </p>
        <p>
         Physiologic reactions are dose and concentration dependent and likely related to direct chemotoxicity, osmotoxicity, or binding of endogenous molecules [
         <a href="#rid2">
          2,20,21
         </a>
         ]. Consequently, physiologic reactions are seen more often in angiography than with diagnostic imaging as the former are associated with higher doses of contrast and usually involve arterial administration directed at end organs.
        </p>
        <p>
         <strong>
          Allergic-like reactions
         </strong>
         are characterized by [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urticaria or pruritus
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sneezing, conjunctivitis or rhinorrhea, or facial edema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hoarseness or stridor, with or without hypoxia (ie, upper airway compromise)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repetitive cough, wheezing, or chest tightness, with or without hypoxia (ie, bronchospasm)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaphylactoid shock (ie, hypotension and tachycardia)
        </p>
        <p>
        </p>
        <p>
         <strong>
          Physiologic reactions
         </strong>
         are characterized by [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient warmth (flushing) or chills
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea or vomiting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary edema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arrhythmia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasovagal reaction (ie, hypotension and bradycardia)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H794791322">
         <span class="h2">
          Reactions with mixed features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reactions with both allergic-like and physiologic features or those where the categorization is ambiguous should be classified and treated as allergic-like. For example, cardiopulmonary arrest is a nonspecific result of either a severe allergic-like or physiologic reaction.
        </p>
        <p class="headingAnchor" id="H2521345610">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Onset of new symptoms following contrast administration should be presumptively evaluated and managed as a contrast reaction. However, definitive diagnosis does require that a complete history be obtained following the acute event to verify that the signs and symptoms were indeed new and temporally associated with exposure to contrast. (See
         <a class="medical medical_review" href="/z/d/html/118730.html" rel="external">
          "Allergy evaluation of immediate hypersensitivity reactions to radiocontrast media"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2219857379">
         <span class="h2">
          Approach to the patient
         </span>
         <span class="headingEndMark">
          —
         </span>
         A patient with a suspected contrast reaction should be immediately evaluated because some reactions require urgent treatment.
        </p>
        <p>
         The diagnostic assessment to classify a contrast reaction includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Determination of responsiveness – Is the patient conscious? If not, resuscitation should be initiated. (See
         <a class="local">
          'Unresponsive patient'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of signs or symptoms in patients who are responsive and verbal – The patient should be asked about symptoms associated with contrast reactions, which may include pruritus, nasal congestion, chest pain, palpitations, lightheadedness, and nausea or vomiting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of verbalization and phonation – Can the patient speak and, if so, is their voice normal? If not, this may be evidence of laryngeal or upper airway edema.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vital signs – The patient's heart and respiratory rate, blood pressure, and oxygen saturation should be measured. Continuous monitoring is initiated if any vital signs are abnormal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin examination of the face, torso, and extremities – The presence of urticaria, erythema, or edema indicate an allergic-like reaction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest auscultation – Patients with acute contrast reactions may develop bronchospasm or pulmonary edema. Bronchospasm may present as wheezing or repetitive dry cough.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3571676037">
         <span class="h2">
          Assessing severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The American College of Radiology manual on contrast media describes signs/symptoms that are commonly seen in different severities of allergic-like and physiologic reactions [
         <a href="#rid1">
          1
         </a>
         ]. In general terms, reaction severity is classified as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild – Reaction is self–limited, does not progress, and rarely requires treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate – Reaction usually requires treatment and may progress to a severe reaction if untreated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe – Reaction is life-threatening and can cause significant morbidity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1785079578">
         <span class="h3">
          Mild allergic-like
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild reactions are usually self-limited [
         <a href="#rid1">
          1
         </a>
         ]. Symptoms include one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limited pruritus or urticaria, localized edema of the skin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limited itchy/scratchy throat
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal congestion/rhinorrhea/sneezing, and/or conjunctivitis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3892132494">
         <span class="h3">
          Moderate/severe allergic-like
         </span>
         <span class="headingEndMark">
          —
         </span>
         For allergic-type reactions, assessing the severity of the reaction is critical, as severe reactions should be treated with immediate
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         . Moderate reactions should be treated because they can progress to severe reactions, although epinephrine is not needed in all cases. Signs and symptoms include one or more of the following [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Widespread pruritus or urticaria, or diffuse skin erythema
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facial edema (moderate - without dyspnea, severe - with dyspnea)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Throat tightness or hoarseness (moderate - without dyspnea, severe - with dyspnea)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wheezing/bronchospasm/cough (moderate - minor or no hypoxia, severe - with hypoxia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaphylactic shock (hypotension plus tachycardia) in severe reactions
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7032227">
         <span class="h3">
          Mild physiologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signs/symptoms include one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient flushing/warmth/chills
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limited nausea/vomiting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache/dizziness/anxiety
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Altered taste
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasovagal reaction that resolves without treatment
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3329240428">
         <span class="h3">
          Moderate/severe physiologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Signs/symptoms include one or more of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Protracted nausea/vomiting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasovagal reaction with symptoms (eg, hypotension with bradycardia, cyanosis, or altered mental status) (moderate - requires and responds to treatment, severe – refractory to treatment)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated chest pain or angina (moderate)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arrhythmia (severe)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Convulsions, seizures (severe)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe hypertension with symptoms of end organ injury (eg, encephalopathy, renal ischemia)
        </p>
        <p>
        </p>
        <p>
         Examples of other rare but severe physiologic reactions include depressed myocardial contractility and cardiogenic pulmonary edema [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1173840853">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute onset of symptoms that immediately follow contrast administration should presumptively be treated as a contrast reaction, unless there is an obvious alternative explanation. Contrast administration, if it is ongoing, should be immediately stopped. The appropriate treatment of a suspected contrast reaction is determined by the patient's signs and symptoms. Treatment is based upon type of reaction and severity.
        </p>
        <p class="headingAnchor" id="H2031212006">
         <span class="h2">
          Unresponsive patient
         </span>
         <span class="headingEndMark">
          —
         </span>
         An unresponsive patient should be resuscitated according to advanced cardiac life support (ACLS) or pediatric advanced life support (PALS). (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">
          "Pediatric advanced life support (PALS)"
         </a>
         .)
        </p>
        <p>
         Once the ACLS or PALS pathways have been initiated, the patient should also be evaluated and treated for a presumed severe contrast reaction (see
         <a class="local">
          'Moderate or severe reactions'
         </a>
         below). Cardiopulmonary arrest can be a nonspecific result of either a severe allergic-like or physiologic reaction. If classification is unclear, an allergic-like reaction should be assumed.
        </p>
        <p class="headingAnchor" id="H1053824746">
         <span class="h2">
          Moderate or severe reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Moderate and severe reactions require immediate initiation of therapy. Following initiation of therapy, these patients should be triaged to the emergency department or to a specialized inpatient bed for continuous monitoring.
        </p>
        <p>
         First steps for all moderate or severe contrast reactions are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Call for help. This would involve calling emergency responders in the outpatient setting and the code team in the emergency department or hospital.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initiate oxygen 6 to 10 L/min by face mask. Oxygen flow should be titrated to the patient's hypoxia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous (IV) access should be obtained if it is not already in place.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A continuous timed log of all interventions should be documented. This should include patient's vital signs, interventions, medications given, dose, and routs of administration.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H199374471">
         <span class="h3">
          Allergic-like
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is equivalent to that for a classic anaphylactic reaction (see
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment"
         </a>
         ). The tables provide rapid overviews of the initial assessment and emergency management of anaphylaxis in adults  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 2
         </a>
         ) and in children  (
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H945431528">
         <span class="h4">
          Epinephrine administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          Epinephrine
         </a>
         is given to patients with an allergic-like contrast reaction with symptoms affecting multiple organ systems (eg, airway compromise [repetitive cough, wheezing, hoarseness] plus cutaneous symptoms [urticaria]) or with anaphylactic shock (ie, hypotension with tachycardia).
         <strong>
          There are no absolute contraindications to epinephrine in such settings.
         </strong>
        </p>
        <p>
         <strong>
          The dosing of
         </strong>
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         <strong>
          is different for intramuscular (IM) and IV administration, and the proper concentration for IV administration is 10-fold less than that of IM administration. Thus, it is critical to use the proper preparation.
         </strong>
        </p>
        <p>
         <strong>
          Intramuscular (preferred)
         </strong>
         —
         <strong>
          Use of autoinjectors and IM administration avoids common dosing errors and is preferred over IV dosing
         </strong>
         because IM dosing is associated with fewer dosing errors and cardiovascular complications [
         <a href="#rid22">
          22,23
         </a>
         ]. IM administration can be repeated in 5 to 15 minutes, and sooner if needed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In adults and adolescents weighing &gt;25 kg, the dose 0.3 mg IM is given using an autoinjector (eg, EpiPen) or 0.3 mL IM of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         drawn up at 1 mg/mL (ampule may be labeled 1:1000) [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In infants and children weighing 10 to 25 kg, the dose is 0.15 mg IM using an autoinjector (eg, EpiPen Jr) and given as 0.15 mL IM of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         drawn up at 1 mg/mL (1:1000).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In infants weighing &lt;10 kg, the dose is 0.1 mg IM using an infant autoinjector (eg, Auvi-q) or given as 0.1 mL IM of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         drawn up at 1 mg/mL (1:1000).
        </p>
        <p>
        </p>
        <p>
         <strong>
          Slow IV infusion
         </strong>
         — If the patient is unresponsive to two doses of IM
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         , a slow IV infusion of epinephrine is the preferred second-line option. However, IV epinephrine infusion requires continuous electronic hemodynamic monitoring and a health care provider with expertise in vasopressor infusion. Thus, this approach may be available in an interventional suite or in the operating room, but will rarely be an option for reactions that occur during diagnostic imaging examinations.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In adults and adolescents weighing &gt;25 kg, IV infusion is initiated at 0.1 mcg/kg/minute and increased every two to three minutes by 0.05 mcg/kg/minute until blood pressure and symptoms improve. The maximum dose is not known and will differ in each patient, but a patient will rarely require a dose exceeding 1 mcg/kg/minute  (
         <a class="graphic graphic_table graphicRef106917" href="/z/d/graphic/106917.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In infants and children weighing &lt;25 kg, IV infusion is initiated at 0.1 to 1 mcg/kg/minute with use of an infusion pump, titrated to blood pressure with continuous cardiac monitoring  (
         <a class="graphic graphic_table graphicRef56049" href="/z/d/graphic/56049.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef66791" href="/z/d/graphic/66791.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         <strong>
          IV bolus (caution)
         </strong>
         —
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          Epinephrine
         </a>
         should be given as an IV bolus only if the IM bolus administration is not effective and the IV infusion option is not available. Epinephrine is also commonly given IV for anaphylaxis in certain settings, such as surgical or cardiac catheterization suites.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In adults and adolescents weighing &gt;25 kg, the dose is 50 to 100 mcg (0.05 to 0.1 mg) and IV bolus is given as a slow push. This is best administered as 0.5 to 1 mL of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         drawn up at 0.1 mg/mL (ampule may be labeled 1:10,000).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We avoid the use of IV boluses in infants and children because data are sparse on the efficacy or safety of this approach.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3754674873">
         <span class="h4">
          Systemic or airway symptoms
         </span>
        </p>
        <p class="headingAnchor" id="H1653414928">
         <span class="h5">
          Hypotension and tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypotension and tachycardia indicate shock.
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          Epinephrine
         </a>
         should be given immediately and there are no contraindications to epinephrine in the setting of anaphylaxis (see
         <a class="local">
          'Epinephrine administration'
         </a>
         above). In addition, large volume fluid resuscitation should be initiated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults should immediately receive 1 to 2 liters of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         IV at the most rapid flow rate possible. Continuous rapid infusion may be necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infants, children, and adolescents receive normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in boluses of 20 mL/kg each over 5 to 10 minutes, and repeated, as needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3717298319">
         <span class="h5">
          Laryngeal edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with hoarseness or inspiratory stridor should be treated with
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         (see
         <a class="local">
          'Epinephrine administration'
         </a>
         above). IV access should be maintained and vital signs should be monitored closely.
        </p>
        <p class="headingAnchor" id="H1624661137">
         <span class="h5">
          Bronchospasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with symptoms of lower airway compromise (ie, wheezing) in combination
         <strong>
          accompanied by symptoms in any other organ system
         </strong>
         (eg, urticaria) should be treated with
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         (see
         <a class="local">
          'Epinephrine administration'
         </a>
         above). In addition, inhaled beta-agonist bronchodilators (eg,
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         ) can be administered by metered dose inhaler (2 to 3 puffs) or as a nebulizer via a facemask. Note that bronchodilators should be considered adjunct to epinephrine as they do not prevent or treat the upper airway mucosal edema or hypotension associated with allergic-like contrast reactions. IV access should be preserved and vital signs should be monitored closely. Mild bronchospasm, without other signs or symptoms, may be treated with bronchodilators alone.
        </p>
        <p class="headingAnchor" id="H489992399">
         <span class="h4">
          Diffuse skin symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         While focal urticaria is often seen in mild reactions to contrast, skin symptoms of urticaria, edema, or erythema that involves large areas or multiple anatomic locations indicate a moderate reaction. If systemic or airway manifestations are also present, the patient should be given
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         (see
         <a class="local">
          'Epinephrine administration'
         </a>
         above).
        </p>
        <p>
         For the skin manifestations, an H1 antihistamine such as
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         25 to 50 mg, administered IM or IV provides symptomatic relief of itching and hives. Note that H1 antihistamines are adjunctive to
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         , as they do not prevent or treat the upper airway mucosal edema or hypotension with allergic-like contrast reactions.
        </p>
        <p class="headingAnchor" id="H4160860766">
         <span class="h3">
          Mild reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild allergic-like reactions (eg, localized hives, urticaria, nasal congestion) can evolve into a moderate or severe reaction and do require observation. Patients should be observed for ≥30 minutes and until the symptoms have resolved. Treatment with an H1 antihistamine, such as
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         25 to 50 mg PO, IM or IV, may be an option to provide symptomatic relief of itching and hives, but is usually unnecessary. Patients treated with sedating H1 antihistamines will not be allowed to drive themselves home and they should be informed of this before initiating treatment.
        </p>
        <p class="headingAnchor" id="H3781664184">
         <span class="h2">
          Physiologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of physiologic reactions is individualized based on the presenting symptoms. Clinical features of a moderate or severe physiologic reaction are:
        </p>
        <p class="headingAnchor" id="H987137988">
         <span class="h3">
          Moderate or severe
         </span>
        </p>
        <p class="headingAnchor" id="H2349747885">
         <span class="h4">
          Hypotension and bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypotension and bradycardia indicate a vasovagal reaction. This is thought to arise from increased vagal tone that depresses cardiac nodal activity and increases peripheral vasodilatation [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Patients should be laid supine with the legs elevated &gt;60 degrees. If there are symptoms of end organ dysfunction (eg, altered mental status, cyanosis), large volume fluid resuscitation should be initiated.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults should immediately receive 1 to 2 liters of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         IV at the most rapid flow rate possible. Continuous rapid infusion may be necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children should receive normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         in boluses of 20 mL/kg IV, each over 5 to 10 minutes, and repeated, as needed.
        </p>
        <p>
        </p>
        <p>
         In patients who do not respond to the initial fluid bolus, an IV bolus of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         is given. (See
         <a class="drug drug_general" href="/z/d/drug information/103444.html" rel="external">
          "Atropine (systemic): Drug information"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adults should receive 0.6 to 1 mg IV every three to five minutes to a maximum dose of 3 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infants, children, and adolescents: 0.02 mg/kg IV for a maximum single dose of 0.5 mg. This may be repeated once in three to five minutes for a maximum dose of 1 mg.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2683854792">
         <span class="h4">
          Hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, hypertension associated with contrast administration is asymptomatic and detected because the patient is being monitored for other reasons, such as for angiography. It is usually self-limited and resolves as the contrast is cleared from the body. Management involves monitoring over several hours until the blood pressure normalizes and continued IV or oral hydration to facilitate urinary contrast clearance. However, patients with symptoms of end organ injury (eg, encephalopathy, renal ischemia) should be treated for hypertensive emergency. (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Hypertensive urgency and emergency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">
          "Evaluation and treatment of hypertensive emergencies in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">
          "Approach to hypertensive emergencies and urgencies in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1299102834">
         <span class="h4">
          Cardiac symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse cardiac events are more frequent in patients with underlying cardiac disease. Management is determined by the presenting symptoms. Cardiac manifestations of a contrast reaction include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest pain (see
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arrhythmia (see
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Management of specific arrhythmias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">
          "Pediatric advanced life support (PALS)", section on 'AHA resuscitation guidelines'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary edema (see
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3497439908">
         <span class="h3">
          Mild signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild physiologic reactions (eg, chills, nausea, metallic taste) usually are self-limited and do not require intervention. Most reactions can be managed with patient counseling and reassurance.
        </p>
        <p class="headingAnchor" id="H784459875">
         <span class="h1">
          IMMEDIATELY FOLLOWING THE REACTION
         </span>
        </p>
        <p class="headingAnchor" id="H3052489434">
         <span class="h2">
          Reaction classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         The contrast reaction should be classified based upon the severity (mild, moderate, or severe) and underlying physiology (allergic-like or physiologic) and these characteristics should be recorded in the patient’s medical record [
         <a href="#rid1">
          1
         </a>
         ] (see
         <a class="local">
          'Allergic-like versus physiologic reaction'
         </a>
         above). This classification is derived from the observed clinical manifestations of the adverse reaction and whether treatment was required.
        </p>
        <p class="headingAnchor" id="H1204837287">
         <span class="h2">
          Documentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any acute contrast reaction should be described in the patient's record. This guides decisions on the need for post-treatment allergy evaluation and on the need for prophylaxis should future contrast administration be necessary. (See
         <a class="medical medical_review" href="/z/d/html/113083.html" rel="external">
          "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Patients with past reactions to contrast'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Patient with history of reaction to gadolinium contrast'
         </a>
         .)
        </p>
        <p>
         The medical record of the contrast reaction should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Causative agent name, dose, and route of administration
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reaction classification based on severity (mild, moderate, or severe) and pathophysiology (ie, allergic-like versus physiologic) (see
         <a class="local">
          'Reaction classification'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical features of the reaction and their duration
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment required
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H823090283">
         <span class="h2">
          Serum tryptase testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurement of serum tryptase can be helpful in patients with severe contrast reactions that were not easily categorized as allergic-like or physiologic (eg, hypotension with flushing). Tryptase is a protease that is released almost exclusively from mast cells and basophils, and an elevation in tryptase is strong evidence that a severe reaction was allergic in nature. Elevations in tryptase are not typically seen after cardiac or pulmonary events or severe physiologic reactions. Although the result does not provide information at the time of the reaction, it can help guide future management if the patient requires additional radiographic studies [
         <a href="#rid26">
          26-30
         </a>
         ]. Several groups have reported elevated serum tryptase levels following severe or fatal immediate reactions to radiologic contrast material [
         <a href="#rid26">
          26,28,31-33
         </a>
         ]. However, the diagnostic and prognostic utility of elevations in serum tryptase for the evaluation of contrast reactions specifically has not been studied [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Tryptase elevations are most often apparent after an allergic reaction involving hypotension. Elevations are transient and best detected if blood is collected between 15 minutes and 3 hours from the onset of symptoms. Instructions for accurate collection are provided  (
         <a class="graphic graphic_table graphicRef72041" href="/z/d/graphic/72041.html" rel="external">
          table 7
         </a>
         ). Serum total tryptase levels normally range from 1 to 11.4 ng/mL. Elevations during anaphylaxis can range from marginally elevated to levels &gt;100 ng/mL. A normal tryptase level does not exclude anaphylaxis, because not all reactions result in tryptase elevations, and mild reaction are rarely associated with tryptase elevations. (See
         <a class="medical medical_review" href="/z/d/html/389.html" rel="external">
          "Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Elevations in anaphylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H621045749">
         <span class="h1">
          CONTRAST READMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to imaging examinations requiring readministration of the contrast agent that caused an adverse reaction varies with the severity of the index reaction and the clinical indication for the imaging examination. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/113083.html" rel="external">
          "Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography", section on 'Patients with past reactions to contrast'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2580391545">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120906.html" rel="external">
          "Society guideline links: Hypersensitivity to iodinated and gadolinium-based contrast agents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2018106248">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The frequency of acute reactions to contrast varies with the contrast type (ie, iodinated versus gadolinium-based) and its molecular properties (eg, ionicity, osmolality, ligand structure). Contrast reactions have been observed with intra-arterial, intravenous (IV), enteral, and intraperitoneal administration, although serious allergic-like reactions are almost always encountered with intravascular administrations. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contrast administration for imaging is associated with a low rate of adverse reactions. Acute reactions usually occur within 20 minutes of exposure but are generally defined as those occurring within an hour. They are classified as allergic-like or physiologic based on the clinical presentation. (See
         <a class="local">
          'Signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A patient with a suspected contrast reaction should be immediately evaluated as some will require urgent treatment. (See
         <a class="local">
          'Evaluation and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute onset of symptoms that immediately follow contrast administration should presumptively be treated as a contrast reaction, unless there is an obvious alternative explanation. Contrast administration, if it is ongoing, should be immediately stopped. The appropriate treatment of a suspected contrast reaction is determined by the patient's signs and symptoms. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An unresponsive patient should be resuscitated according to advanced cardiac life support (ACLS) or pediatric advanced life support (PALS) (see
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6392.html" rel="external">
          "Pediatric advanced life support (PALS)"
         </a>
         ). Once the ACLS or PALS pathways have been initiated, the patient should also be evaluated and treated for a presumed severe contrast reaction. (See
         <a class="local">
          'Unresponsive patient'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Moderate or severe signs or symptoms require immediate initiation of therapy. Allergic-like reactions (ie, diffuse urticaria, cutaneous edema, or erythema, upper or lower airway compromise, or anaphylactoid shock) are treated with intramuscular (IM)
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         in most cases; treatment of physiologic reactions (ie, symptomatic vasovagal reaction, arrhythmia, angina, seizure, symptomatic hypertension, and intractable nausea and vomiting) are tailored to the specific symptoms. Following initiation of therapy, these patients should be triaged to the emergency department or be hospitalized for continued monitoring. (See
         <a class="local">
          'Moderate or severe reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mild reactions usually are self-limited and do not require intervention. Physiologic reactions (eg, chills, nausea, metallic taste) are transient and can be managed with patient counseling and reassurance. However, mild allergic-like reactions (eg, localized hives, urticaria, nasal congestion) can rarely evolve into a moderate or severe reaction and do require observation for ≥30 minutes or until the symptoms resolve. (See
         <a class="local">
          'Mild signs and symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The contrast reaction should be classified based upon the severity (mild, moderate, or severe) and underlying physiology (allergic-like or physiologic). This classification is derived from the observed clinical manifestations of the adverse reaction and whether treatment was required. (See
         <a class="local">
          'Reaction classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Any acute contrast reaction should be described in the patient's record. This guides decisions on the need for post-treatment allergy evaluation and on the need for prophylaxis should future contrast administration be necessary. (See
         <a class="local">
          'Immediately following the reaction'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          American College of Radiology. Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, Version 10.3. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf (Accessed on July 15, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol 1991; 157:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997; 203:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf GL, Arenson RL, Cross AP. A prospective trial of ionic vs nonionic contrast agents in routine clinical practice: comparison of adverse effects. AJR Am J Roentgenol 1989; 152:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behzadi AH, Zhao Y, Farooq Z, Prince MR. Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis. Radiology 2018; 286:731.
          </a>
         </li>
         <li class="breakAll">
          European Society of Urogenital Radiology. ESUR Guidelines on Contrast Media v10.0 http://www.esur.org/guidelines/ (Accessed on July 05, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001; 176:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang CL, Cohan RH, Ellis JH, et al. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol 2008; 191:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortelé KJ, Oliva MR, Ondategui S, et al. Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital. AJR Am J Roentgenol 2005; 184:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009; 193:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caro JJ, Trindade E, McGregor M. The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis. AJR Am J Roentgenol 1991; 156:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011; 196:W138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol 1996; 167:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forbes-Amrhein MM, Dillman JR, Trout AT, et al. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children. Invest Radiol 2018; 53:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dillman JR, Ellis JH, Cohan RH, et al. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 2007; 189:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behzadi AH, Zhao Y, Farooq Z, Prince MR. Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis. Radiology 2018; 286:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li A, Wong CS, Wong MK, et al. Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates. Br J Radiol 2006; 79:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp AF, Mortele KJ, Cho YD, et al. Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients. Acta Radiol 2008; 49:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology 1997; 203:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almén T. The etiology of contrast medium reactions. Invest Radiol 1994; 29 Suppl 1:S37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawano T, Scheuermeyer FX, Stenstrom R, et al. Epinephrine use in older patients with anaphylaxis: Clinical outcomes and cardiovascular complications. Resuscitation 2017; 112:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract 2015; 3:76.
          </a>
         </li>
         <li class="breakAll">
          Royal College of Radiology. Standards for intravascular contrast administration to adult patients, 3rd ed. https://www.rcr.ac.uk/sites/default/files/Intravasc_contrast_web.pdf (Accessed on December 05, 2018).
         </li>
         <li class="breakAll">
          European Society of Urogenital Radiology. ESUR guidelines on contrast media. http://www.esur.org/guidelines/ (Accessed on December 05, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laroche D, Aimone-Gastin I, Dubois F, et al. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology 1998; 209:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewachter P, Mouton-Faivre C, Felden F. Allergy and contrast media. Allergy 2001; 56:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockow K, Vieluf D, Püschel K, et al. Increased postmortem serum mast cell tryptase in a fatal anaphylactoid reaction to nonionic radiocontrast medium. J Allergy Clin Immunol 1999; 104:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewachter P, Laroche D, Mouton-Faivre C, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol 2011; 77:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockow K, Sánchez-Borges M. Hypersensitivity to contrast media and dyes. Immunol Allergy Clin North Am 2014; 34:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ring J, Simon RA, Arroyave CM. Increased in vitro histamine release by radiographic contrast media in patients with history of incompatibility. Clin Exp Immunol 1978; 34:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laroche D. Immediate reactions to contrast media: mediator release and value of diagnostic testing. Toxicology 2005; 209:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005; 60:150.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2075 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : American College of Radiology. Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, Version 10.3. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf (Accessed on July 15, 2020).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1950858" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2343107" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169676" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2495706" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A prospective trial of ionic vs nonionic contrast agents in routine clinical practice: comparison of adverse effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29356629" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29356629" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11373197" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Trends in adverse events after IV administration of contrast media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647910" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15615946" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19770337" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1825900" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257854" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incidence of immediate gadolinium contrast media reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8819369" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Adverse reactions to gadolinium contrast media: a review of 36 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29337841" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18029897" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28846495" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16632615" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Acute adverse reactions to magnetic resonance contrast media--gadolinium chelates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18651252" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevalence of acute reactions to iopromide: postmarketing surveillance study of 74,717 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169677" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8071042" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The etiology of contrast medium reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28069483" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Epinephrine use in older patients with anaphylaxis: Clinical outcomes and cardiovascular complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25577622" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25577622" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25577622" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9769830" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mechanisms of severe, immediate reactions to iodinated contrast material.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11251409" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Allergy and contrast media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10400867" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Increased postmortem serum mast cell tryptase in a fatal anaphylactoid reaction to nonionic radiocontrast medium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19833466" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Immediate reactions following iodinated contrast media injection: a study of 38 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25017677" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Hypersensitivity to contrast media and dyes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/83924" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Increased in vitro histamine release by radiographic contrast media in patients with history of incompatibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10823122" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Postmortem findings after fatal anaphylactic reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15767035" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Immediate reactions to contrast media: mediator release and value of diagnostic testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15647034" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Management of hypersensitivity reactions to iodinated contrast media.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
